AbbVie Inc. (ABBV)
Track the next or latest earnings date for AbbVie Inc., review consensus estimates, and see cached AI analysis for recent quarterly results.
Recent earnings news
Barchart.com · 2026-04-02T05:47:08Z
AbbVie will release its first-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.
Merck Just Made a Big Bet on a New Cancer Growth EngineMarketBeat · 2026-03-31T11:58:00Z
Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.
Latest earnings date
Time not specified
Fiscal quarter: 2025-12-31
EPS estimate: $3.20
Revenue estimate: N/A
Market cap: $390.15B
AI earnings summary
Management anticipates 9.5% sales growth in 2026, with continued strong performance from Skyrizi and Rinvoq expected to drive growth despite ongoing HUMIRA declines. The company provided 2026 adjusted EPS guidance framework with expectations for cleaner earnings trajectory with minimal acquired IPR&D charges.
Sentiment and reaction
Sentiment score: +70.00%
Post-earnings price reaction: -6.45%
EPS
Estimate: $3.20
Actual: $2.71
Surprise: -15.31%
Revenue
Estimate: $16.42B
Actual: $16.62B
Surprise: +1.22%
Financial highlights
• Revenue of $16.62 billion for Q4 2025, representing 8.6% YoY sales growth • Full-year 2025 revenue of $61.16 billion, up 8.57% from prior year ($56.33 billion) • Strong immunology portfolio performance with 18% growth led by Skyrizi and Rinvoq • HUMIRA outperformance despite ongoing biosimilar erosion • Adjusted diluted EPS grew 25% YoY, beating estimates despite pre-announced IPR&D charges • Net income of $4.23 billion for full year 2025, down 0.28% from prior year • Operating performance driven by newer immunology drugs offsetting legacy product declines
Recent earnings history
Browse the calendar week| Date | Quarter | Report window | EPS est. | Revenue est. |
|---|---|---|---|---|
| Feb 04, 2026 | 2025-12-31 | Time not specified | $3.20 | N/A |